Vincristine pharmacokinetic, tumour uptake and therpeutic characteristics wme invesgated here in order to elucidate the processes underlying the ha e dFicacy observed for vincristne entrapped in small (120 nm) distearoylphosphatidychoie/cholesteroI liposomes Plam vincistine levels after intravenous (i.v.) The use of liposomes as delivery vehicles for anti-c.n. drugs has expanded beyond the initial focus on improving the therapeutic activity of doxorubicin (Gabizon, 1994) to include a wide range of anthracyclines (Schwendener et al., 1991; Forssen et al., 1992; Gabizon, 1992; Perez-Soler et al., 1994a) , platinum-based compounds (Gondal et al., 1993; Perez-Soler et al., 1994b) , nucleoside analogues (Schwendener et al., 1989; Allen et al., 1992) and vinca allkaloids (Mayer et al., 1990a Vaage et al., 1993) . Previous reports from our laboratories (Mayer et al., 1990a and others (Vaage et al., 1993) have demonstrated that encapsulation of vincristine inside appropriately designed liposomes can yield improved therapy over free vinmistine in ascitic and solid tumour models. However, the mechanism(s) whereby these liposomes improve the therapeutic activity of vincristine are not well understood.
The use of liposomes as delivery vehicles for anti-c.n. drugs has expanded beyond the initial focus on improving the therapeutic activity of doxorubicin (Gabizon, 1994) to include a wide range of anthracyclines (Schwendener et al., 1991; Forssen et al., 1992; Gabizon, 1992; Perez-Soler et al., 1994a) , platinum-based compounds (Gondal et al., 1993; Perez-Soler et al., 1994b) , nucleoside analogues (Schwendener et al., 1989; Allen et al., 1992) and vinca allkaloids (Mayer et al., 1990a Vaage et al., 1993) . Previous reports from our laboratories (Mayer et al., 1990a and others (Vaage et al., 1993) have demonstrated that encapsulation of vincristine inside appropriately designed liposomes can yield improved therapy over free vinmistine in ascitic and solid tumour models. However, the mechanism(s) whereby these liposomes improve the therapeutic activity of vincristine are not well understood.
Free vincristine exerts its antineoplastic effects by preventing tubulin polymerisation as well as inducing depolymerisation through its high binding affinity for tubulin, thus arresting cell mitosis during metaphase (Zhou and Rahmani, 1992 ). As such, this agent is cell cycle specific and its drug-mediated therapeutic responses are dependent on the maintenance of therapeutic drug levels in tumours for extended periods of time (Horton et al., 1988) . This relationship has provided the basic rationale for admiing vimcrisine encapsulated in a liposome-based drug carrier. Specfically, liposomes have been shown to provide an extended drug reservoir in the blood compartment for a variety of anti-cancer agents (Gabizon and Paphadjopoulos, 1988; Mayer et al., 1989; Allen et al., 1992; Gabizon, 1992) . Previous investigations with liposomal viristine support this concept and demonstrated that the anti-tumour activity of these systems is related to the longevity of the drug in the circulation . Small (120 nm) liposomes composed of distearoylphosphatidylcholine (DSPC) and cholesterol provided increased blood ciculation lifetimes and improved therapeutic activity relative to other liposomes tested. Liposomal formulations that were removed rapidly from the circulation by the reticulo endothelial system (RES)
Correspondence: LD Mayer Received 10 August 1994; revised 20 October 1994; accepted 21 October 1994 or released the entrapped vincristine over very short periods of time displayed inferior anti-tumour activity. Recently, we have shown that inclusion of monosialoganglioside (GM,) and utilising liposomes with an entrapped buffer pH of 2.0 synergstically combine to further improve the circulation longevity and efficacy of liposomal vincristine (Boman et al., 1994) .
The apparent correlation observed between vicristine circulation longevity and therapeutic activity is complicated by the fact that liposomal systems displaying increased drug drculation lifetimes (small liposomes composed of saturated phospholipids and cholesterol) would also be expected to be superior in their ability to deliver drug directly to the tumour site. A growing body of evidence is indicating that small liposomes are capable of preferentially extravasating endothelial barriers present in tumour vasculature and accumulating in the extravascular space of tumours (Huang et al., 1992a (Huang et al., , 1993 Bally et al., 1994) . methods.
-
PhvmNWlon o ip_ vir LD Mayer et at 484 liposomal form (Figure 1) . Plasma vincristine levels after injection of free drug were somewhat lower in L1210-bearing mice than in control mice, however this difference was statistically different only at the 1 h time point.
Further studies were conducted here to determine whether the elevated plasma drug levels observed with liposome entrapped vincristine correlated with increased drug accumulation in the peritoneum of mice bearing the L1210 tumour subsequent to i.v. administration. Liposomal lipid levels were also monitored in order to assess the direct uptake of liposomes into the peritoneal tumour site. Figure 2a (Figure 4) . Owing to the low levels of drug in the plasma at 24 h for free vincnrstine in B16/BL6-bearing mice (below mi ium detection limit of 5.0 ng ml1' plasma), definitive comparisons of free and liposomal vincristine for these animals could not be made. However, given the minimum detection limit, the data indicate that 24 h drug Figure 5b . Tumour-associated liposomal lipid increases steadily over the first 24 h post administration and then slowly over the remaining 48 h of the experimental study period. This is in contrast to the L1210 ascites tumour model, in which liposomal lipid levels in the peritoneal tumour site decreased after 24 h (Figure 2b ). However, both tumour models are similar in that the tumour-associated drug-to-lipid ratios compare favourably with the drug-tolipid ratio observed in the circulation.
For the B16 tumour model employed here, we tested the anti-tumour activity and tumour accumulation in wellestablished solid tumours whose pretreatment weights 14 days after s.c. tumour implantation were in the range of 0.2-0.5 g (Figure 6a and b). Untreated tumours grow to a size of approximately 2.5 g within 22 -24 days post tumour inoculation, at which time the mice are euthanised. Figure 6a demonstrates that free vincristine, when administered i.v. up to its maximum tolerated dose, provides no therapeutic activity against the B16/BL6 solid tumour. Tumours continue to grow despite the occurrence of drug-induced toxicity, especially at the 3 mg kg-' dose, when weight loss nadirs can reach 15-20% of total body weight (data not shown).
Administration of a single dose of vincnrstine entrapped inside 120 nm DSPC-cholesterol, however, induces a significant therapeutic effect (Figure 6b ). Liposomal vincristine at 2 mg kg-' and 3 mg kg-' inhibits tumour growth for approximately 6 days after drug injection and maximal activity is obtained with the 3 mg kg-' dose. Subsequently, these tumours resume a growth rate similar to untreated controls.
Comparison of tumour drug levels and systemic exposure of vincristine to healthy tissue after administration offree and liposomal vincristine
The studies described above demonstrate that the improved therapeutic activity observed for vincristine encapsulated in 120 nm DSPC-cholesterol liposomes correlates with increased delivery of drug to the tumour site. Further, as shown here and previously , liposomal vincristine systems exhibiting enhanced anti-tumour activity also display extended circulation lifetimes and increased drug retention while circulating in the blood compartment. However, these data are insufficient to determine whether the increased anti-tumour activity is related to a pool of vincristine that is slowly released systemically from circulating liposomes or to vincristine that is directly delivered by the liposomes to the tumour. In order to differentiate between these two possible mechanisms, we compared the accumulation of vincristine in tumour and healthy muscle tissue after i.v. administration of the drug in free and liposomal form. Muscle was selected as an indicator for systemic exposure to unencapsulated vincristine on the basis of previous reports indicating that liposomes display very low uptake levels in this tissue . Therefore, the level of drug (Figure 7a) . The 0-72 h trapezoidal area under the curve (AUC) value of 5.01 pg h g9' determined for muscle tissue is 2.6-fold lower than that observed for tumour tissue (13.3 .Lg h g-'), indicating increased total drug exposure to the neoplastic site (Table I) . Interestingly, peak tissue drug uptake levels are similar for both tissues (0.75jIgg-g muscle and 0.77ILgg-' tumour achieved at 15 min and I h respectively). In contrast, vincristine administered in liposomal form exhibits a dramatic in- 4.3 jLg h g' respectively, reflecting a 12.6-fold increase in total drug exposure to tumour tissue (see Table I ). The data shown in Figure 8 demonstrate that tumour associated liposomal lipid increases over 24-48 h to achieve levels in excess of 100 lOg g-' tumour compared with peak muscle levels of 2.1 iLg lipid per g of tissue at 48 h. The corresponding liposomal lipid of 0-72 h trapezoidal AUC value for the B16/BL6 tumour of 5530 iLg h g-' tissue was approximately 44-fold larger than the AUC obtained in muscle tissue (125 1gghg-' muscle, Table I ).
Similar to the B16/BL6 tumour model, 0-72 h trapezoidal AUC values for the L1210 tumour reveal that total vincristine exposure to the tumour-bearing peritoneum is dramatically increased when the drug is administered in liposomal form. Specifically, injection of free vincristine results in an AUC of 0.264iLgh per peritoneum, whereas an AUC of 3.4;Lg h per peritoneum is obtained with liposomal vincristine (Table I) . This difference reflects a 12.9-fold increase in drug exposure for the liposomal formulation and is substan- al., l990a, 1993) .
The ability to determine the relative contributions of circulating and tumour-associated liposomes toward the antitumour activity of liposomal vncristine has been complicated by the fact that formulations exhibiting enhanced tumour accumulation also display extended circulation lifetmes.
Specifically, although circulating vristine levels are inased over several days when the drug is encapsulated in DSPC-cholesterol liposomes, approximately 85% of the drug is released over 24 h from lposomes in the plasma (Figures 1 and 2) . Therefore, it would not be unexpected for increased tumour vincristn levels to arise from drug that has leaked from liposomes in the central blood compartment. Both the systemic infusion and direct tumour delivery models could account for the 12.9-and 4.1-fold increase in AUC values observed for liposomal vincristine in the L1210 and B16/BL6 tumours respectively. However, if the systemic infusion model is correct, then other tissues that take up vicncrsti but do not take up liposomes should also display increased vincristine AUC values when liposomes are employed, compared with unencapsulated drug.
Total plasma drug concentrations are elevated > 100-fold over the entire time course when vinistie is entrapped in 120 nm DSPC-cholesterol liposomes. Under these conditions, however, total drug exposure to muscle tissue is actually decreased by approximately 14% and peak muscle vincrisin kvels are decreased by 83% compared with mice injected with free drug. This is in contrast to the 4.1-fold increase in total drug exposure to tumour tissue observed for liposomal vincristine compared with free drug ( Figure 5 and Table I ). Further, liposomal lipid levels observed in these two tissues confirm that liposomal vincristine does not accumulate to any significnt degree into muscle tissue. The 4 h and 24 h muscle drug-to-lipid ratios of >0.13 and 0.07 obtained after injection of liposomal vicristine are significantly higher than the respective plasma values of 0.028 and 0.006 and indicate that drug levels observed in muscle tissue for this formulation most likely are derived from free vncristine that has leaked from liposomes in the circulation. These results also suggest that systemically rekased drug does not contribute significntly to the th peutic activity observed for liposomal preparations. Rather, the increase in vincristine's anti-tumour potency when encapsulated in small DSPC-cholesterol liposomes appears related to the delvery of vincrisine directly to the tumour site by the carrier system and subsequent long-term exposure of drug to resident tumour cels.
The mechanism of action for liposomal vinristine emerging from the analysis here has Important implications for the design and future optimisation of vesicle systems for therapeutic use. Liposomes that have accumulated in tumours would be expected to slowly release entrapped vincristin, effectively providing a disease site-specific drug infusion reservoir. This is similar to mechanisms proposed recently for doxorubicin encapsulated in sterically stabilised liposomes (Yuan et al., 1994) . Alternatively, vincristinecontaining liposomes may be engulfed and processed by tumour-associated phagocytic cells, resulting in a facilitated release of vincristine within the tumour, as observed for other liposomal drugs (Storm et al., 1988) . In both cases, the use of enhand circulation longevity to increase tumour delivery of virstine will require improved drug retention propErtis for the liposomal carrier. The relationship between drug retention and tumour drug delivery/therapy has been corroborated by recent investigations demonstrating the ability of pH 2.0 liposomes containing GM, to improve yincristin retention and anti-tumour activity (Boman et al., 1994 
